Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Cecchini

Showing results (11-20 of 63) with videos related to

Pageof 7
Sort By:
Journal of Cutaneous Medicine and Surgery|February 5, 2021
Superficial Granulomatous Pyoderma Gangrenosum Involving the Face: A Case Series of Five Patients and a Review of the LiteratureEran Shavit, Michael Cecchini, James J Limacher, et al.
The Oncologist|March 17, 2021
Publication Bias in Gastrointestinal Oncology Trials Performed over the Past DecadeGabrielle W Peters, Weiwei Tao, Wei Wei, et al.
The Lancet. Oncology|January 6, 2018
Introduction to the Yale Precision Medicine Tumor BoardMichael Cecchini, Zenta Walther, Jeffrey L Sklar, et al.
Annals of Surgical Oncology|May 30, 2025
A Feasibility Study of Mass-Based Response Drug Screening to Guide Personalized Hyperthermic Intraperitoneal Chemotherapy for Appendiceal and Colorectal Adenocarcinoma with Peritoneal MetastasisJustin M Bader, Ava Ospina, Sean Liu, et al.
The Lancet. Oncology|January 6, 2018
Yale Cancer Center Precision Medicine Tumor Board: two patients, one targeted therapy, different outcomesMichael Cecchini, Zenta Walther, Jeffrey L Sklar, et al.
BMC Cancer|July 15, 2016
Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort studyPashtoon M Kasi, Daisuke Kotani, Michael Cecchini, et al.
Dermatology and Therapy|April 20, 2026
Efficacy and Safety of the PD-1 Agonist JNJ-67484703 in Participants with Atopic Dermatitis: Phase 2a, Randomized, Double-Blind, Placebo-Controlled Trial ResultsMichael Cecchini, Bartlomiej Kwiek, Fang Liu-Walsh, et al.
Cancer Metastasis Reviews|April 23, 2026
Evolving therapeutics in colorectal cancer peritoneal metastasesJustin M Bader, Nicole Aguirre, Kurt S Schultz, et al.
The Lancet. Oncology|March 4, 2021
Yale Cancer Center Precision Medicine Tumor Board: molecular findings alter a diagnosis and treatment planJoanna A Gibson, Karin E Finberg, ILKe Nalbantoglu, et al.
Journal for Immunotherapy of Cancer|September 11, 2025
High MGMT expression identifies aggressive colorectal cancer with distinct genomic features and immune evasion propertiesJanie Yue Zhang, Barani Kumar Rajendran, Shruti S Desai, et al.
Pageof 7

Showing results (11-20 of 63) with videos related to

Sort By:
Pageof 7
Journal of Cutaneous Medicine and Surgery|February 5, 2021
Superficial Granulomatous Pyoderma Gangrenosum Involving the Face: A Case Series of Five Patients and a Review of the LiteratureEran Shavit, Michael Cecchini, James J Limacher, et al.
The Oncologist|March 17, 2021
Publication Bias in Gastrointestinal Oncology Trials Performed over the Past DecadeGabrielle W Peters, Weiwei Tao, Wei Wei, et al.
The Lancet. Oncology|January 6, 2018
Introduction to the Yale Precision Medicine Tumor BoardMichael Cecchini, Zenta Walther, Jeffrey L Sklar, et al.
Annals of Surgical Oncology|May 30, 2025
A Feasibility Study of Mass-Based Response Drug Screening to Guide Personalized Hyperthermic Intraperitoneal Chemotherapy for Appendiceal and Colorectal Adenocarcinoma with Peritoneal MetastasisJustin M Bader, Ava Ospina, Sean Liu, et al.
The Lancet. Oncology|January 6, 2018
Yale Cancer Center Precision Medicine Tumor Board: two patients, one targeted therapy, different outcomesMichael Cecchini, Zenta Walther, Jeffrey L Sklar, et al.
BMC Cancer|July 15, 2016
Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort studyPashtoon M Kasi, Daisuke Kotani, Michael Cecchini, et al.
Dermatology and Therapy|April 20, 2026
Efficacy and Safety of the PD-1 Agonist JNJ-67484703 in Participants with Atopic Dermatitis: Phase 2a, Randomized, Double-Blind, Placebo-Controlled Trial ResultsMichael Cecchini, Bartlomiej Kwiek, Fang Liu-Walsh, et al.
Cancer Metastasis Reviews|April 23, 2026
Evolving therapeutics in colorectal cancer peritoneal metastasesJustin M Bader, Nicole Aguirre, Kurt S Schultz, et al.
The Lancet. Oncology|March 4, 2021
Yale Cancer Center Precision Medicine Tumor Board: molecular findings alter a diagnosis and treatment planJoanna A Gibson, Karin E Finberg, ILKe Nalbantoglu, et al.
Journal for Immunotherapy of Cancer|September 11, 2025
High MGMT expression identifies aggressive colorectal cancer with distinct genomic features and immune evasion propertiesJanie Yue Zhang, Barani Kumar Rajendran, Shruti S Desai, et al.
Pageof 7